Last reviewed · How we verify

Planned Parenthood Federation of America — Portfolio Competitive Intelligence Brief

Planned Parenthood Federation of America pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Subcutaneous depot medroxyprogesterone acetate Subcutaneous depot medroxyprogesterone acetate marketed Progestin contraceptive Progesterone receptor Contraception

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 1 shared drug class
  2. University of Alabama at Birmingham · 1 shared drug class
  3. University of Sao Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Planned Parenthood Federation of America:

Cite this brief

Drug Landscape (2026). Planned Parenthood Federation of America — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/planned-parenthood-federation-of-america. Accessed 2026-05-17.

Related